meetings

Transcript, Meeting 10, Opening Remaks & Session 1

DR. GUTMANN:  Good morning, everybody.  I'm Amy Gutmann.  I'm president of the University of Pennsylvania and chair of the Presidential Commission for the Study of Bioethical Issues.  On behalf of my vice chair Jim Wagner who is president of Emory University and myself I welcome you all to this our tenth meeting.

                             Before we continue and in order for us to continue officially I want to recognize our designated federal officer, Dr. Lisa Lee.  Lisa, would you please stand up?  Lisa is the executive director of our Commission.  Thank you.

Date

Wed, 08/01/2012

Transcript, Meeting 10, Session 11

               DR. GUTMANN:  Thank you all for giving us such stimulating presentations.  And this is an opportunity for us to pick your brains one more time, and it's become a tradition to begin with a question of asking you to pinpoint one single issue that you think is most important, but I want to refine that question somewhat in light of your excellent presentations.

Date

Thu, 08/02/2012

Transcript, Meeting 10, Session 10

                             DR. WAGNER:  Gentlemen, welcome. To our panelists, we have been eager ‑‑ I was going to say "agonizing" (laughter) ‑‑ but we have been eager to have more facts, more information, and to zero-in on what is the key information needed for decision-making regarding pediatric medical countermeasures research.  And we are hoping these speakers are going to help inch us ‑‑ in fact, feel free to move more than inch ‑‑ in this conversation, gentlemen.

Date

Thu, 08/02/2012

Transcript, Meeting 10, Session 9

DR. GUTMANN:  I am going to get started because we have a wonderful guest.

                             Please take seats.

                             Our next session will focus on national-level review of certain types of pediatric research.  Initially contemplated in the late 1970s by one of our predecessor bioethics commissions, the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, this type of national-level review is also codified in federal regulations.

Date

Thu, 08/02/2012

Transcript, Meeting 10, Session 8

DR. WAGNER:  Okay.  If we can have the Commissioners take their seats?

                             And we will begin our Session 8, after a very productive Session 7.  Thank you, Amy.  That was excellent.

                             And so, at this point in our meeting, we do switch gears.  We have been talking about genomics and whole genomic sequencing.  We are going to shift to medical countermeasures.

Date

Thu, 08/02/2012

Transcript, Meeting 10, Sessions 5 & 6

DR. GUTMANN:  Welcome back, everyone.  If you would please take a seat we will get started.  This is the beginning of a series of sessions in which we as members of the Commission will discuss in real potential form possible draft -- well, these are draft recommendations and we'll discuss them as a Commission. 

Date

Wed, 08/01/2012

Transcript, Meeting 10, Session 4

DR. WAGNER:  But don't go anywhere. No, please don't go anywhere.  In fact, what we want to do is invite back now all of our other morning's guests and speakers, if they would join us.  And I think we've got name tags up here to remind you who you are.

Date

Wed, 08/01/2012

Transcript, Meeting 10, Session 3

DR. GUTMANN:  Commission members, please be seated.  Welcome back, everybody.  We are about to welcome Dr. Bartha Knoppers.  And Dr. Knoppers will speak with us about consent and return of research results.

                             Dr. Knoppers is the director of the Center of Genomics and Policy at McGill University in Canada.  She has served as the chair of the International Ethics Committee of the Human Genome Organization and as a member of the UNESCO International Bioethics Committee which drafted the Universal Declaration on the Human Genome and Human Rights. 

Date

Wed, 08/01/2012

Transcript, Meeting 10, Session 7

DR. GUTMANN:  Okay.  We are going to jump right into our first session.

                             So, yesterday we began with some of our recommendations and had a very, I thought, productive discussion of them.  Today we are going to continue with them.

                             They clump into two big categories.  One is consent to hold genome sequencing and to the possible findings and how they will be treated, and the other is oversight of them.

Date

Thu, 08/02/2012

TRANSCRIPT, Meeting 9, Session 8

DR. WAGNER:  And if you were present for the prior roundtable, you're prepared for the genre of question we open up with.  And as the ‑‑ as our Commission thinks about how we want to talk about privacy and access to genomic data, or for that matter how it is processes of collection and management, if you will, have ‑‑ we'd like you to give some thought to one thing you would certainly expect to read there.  A particular aspect of this that you would hope we would address.

          Greg, you made the mistake of nodding.  So may I ask you perhaps to go first?

Date

Thu, 05/17/2012

Pages

Subscribe to RSS - meetings